APOBEC3B and breast carcinoma: By contrast, the authors observed no correlation between APOBEC3B expression and sensitivity to the DNA-damaging and antimetabolite drugs in their small panel of breast cancer cell lines—results we confirmed in GDSC1000 (Additional file 2: Table S1a, b).